DK0760668T3 - Anvendelse af magnesiumbaserede produkter til behandling eller forebyggelse af neoplastiske og autoimmune sygdomme - Google Patents

Anvendelse af magnesiumbaserede produkter til behandling eller forebyggelse af neoplastiske og autoimmune sygdomme

Info

Publication number: DK0760668T3
Authority: DK; Denmark
Prior art keywords: magnesium; pharmaceutically acceptable; salt; treat; magnesium salt
Prior art date: 1994-05-25

Application number

DK95920208T

Other languages

English (en)

Inventor

Giampiero Valletta

Original Assignee

Giampiero Valletta

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-25

Filing date

1995-05-24

Publication date

2003-03-31

1995-05-24 Application filed by Giampiero Valletta filed Critical Giampiero Valletta

2003-03-31 Application granted granted Critical

2003-03-31 Publication of DK0760668T3 publication Critical patent/DK0760668T3/da

Links

FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title abstract 3
229910052749 magnesium Inorganic materials 0.000 title abstract 3
239000011777 magnesium Substances 0.000 title abstract 3
230000001613 neoplastic effect Effects 0.000 title abstract 3
208000023275 Autoimmune disease Diseases 0.000 title 1
159000000003 magnesium salts Chemical class 0.000 abstract 4
XZTWHWHGBBCSMX-UHFFFAOYSA-J dimagnesium;phosphonato phosphate Chemical compound [Mg+2].[Mg+2].[O-]P([O-])(=O)OP([O-])([O-])=O XZTWHWHGBBCSMX-UHFFFAOYSA-J 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
229940091250 magnesium supplement Drugs 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
208000009956 adenocarcinoma Diseases 0.000 abstract 1
230000037396 body weight Effects 0.000 abstract 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 abstract 1
229940069446 magnesium acetate Drugs 0.000 abstract 1
235000011285 magnesium acetate Nutrition 0.000 abstract 1
239000011654 magnesium acetate Substances 0.000 abstract 1
229960001983 magnesium aspartate Drugs 0.000 abstract 1
OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 abstract 1
229960004658 magnesium lactate Drugs 0.000 abstract 1
235000015229 magnesium lactate Nutrition 0.000 abstract 1
239000000626 magnesium lactate Substances 0.000 abstract 1
RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 abstract 1
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
239000011726 vitamin B6 Substances 0.000 abstract 1
235000019158 vitamin B6 Nutrition 0.000 abstract 1
229940011671 vitamin b6 Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK95920208T 1994-05-25 1995-05-24 Anvendelse af magnesiumbaserede produkter til behandling eller forebyggelse af neoplastiske og autoimmune sygdomme DK0760668T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ITRM940328A IT1272994B (it)	1994-05-25	1994-05-25	Uso di prodotti contenenti magnesio nella terapia e nella profilassi di malattie neoplastiche e di malattie di tipo autoimmunitario.-
PCT/IT1995/000089 WO1995031991A2 (en)	1994-05-25	1995-05-24	Use of magnesium-based products for the treatment or prophylaxis of neoplastic and autoimmune diseases

Publications (1)

Publication Number	Publication Date
DK0760668T3 true DK0760668T3 (da)	2003-03-31

Family

ID=11402556

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95920208T DK0760668T3 (da)	1994-05-25	1995-05-24	Anvendelse af magnesiumbaserede produkter til behandling eller forebyggelse af neoplastiske og autoimmune sygdomme

Country Status (15)

Country	Link
US (2)	US6248368B1 (da)
EP (1)	EP0760668B1 (da)
JP (1)	JP3721196B2 (da)
KR (1)	KR100363031B1 (da)
CN (1)	CN1111414C (da)
AT (1)	ATE229809T1 (da)
AU (1)	AU691617B2 (da)
CA (1)	CA2190847C (da)
DE (1)	DE69529213T2 (da)
DK (1)	DK0760668T3 (da)
ES (1)	ES2188663T3 (da)
IT (1)	IT1272994B (da)
PT (1)	PT760668E (da)
RU (2)	RU2163487C2 (da)
WO (1)	WO1995031991A2 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1076197C (zh) *	1997-08-20	2001-12-19	许跃远	一种治疗乳腺疾病的药
US6639265B2 (en)	2000-01-26	2003-10-28	Semiconductor Energy Laboratory Co., Ltd.	Semiconductor device and method of manufacturing the semiconductor device
US6506412B2 (en) *	2000-11-29	2003-01-14	Sciencebased Health	Treatment of dry eye syndrome
US7097860B2 (en) *	2001-08-03	2006-08-29	Aaron Moshenyat	Method and composition for treatment of inflammatory and inflammation-related disorders
US6537590B1 (en) *	2002-02-19	2003-03-25	Troy J. Lee	Solution and the method of making the same for the treatment of osteoarthritis
RU2232560C2 (ru) *	2002-04-05	2004-07-20	Саратовский научно-исследовательский институт травматологии и ортопедии	Способ лечения аутоиммунного артрита у животных
US7247328B2 (en) *	2002-05-31	2007-07-24	Zinpro Corporation	Chromium (III) alpha amino acid complexes
US7129375B2 (en)	2002-10-16	2006-10-31	Zinpro Corporation	Metal complexes of α amino dicarboxylic acids
RU2237466C1 (ru) *	2003-02-06	2004-10-10	Покатилов Игорь Олегович	Способ коррекции избыточного жироотложения проблемных зон
RU2263316C2 (ru) *	2003-04-04	2005-10-27	Военно-медицинский институт Федеральной пограничной службы Российской Федерации при Нижегородской государственной медицинской академии (ВМИ ФПС РФ при НГМА)	Способ диагностики дефицита магния при внутренней патологии
DE602004018534D1 (de) *	2003-10-10	2009-01-29	Kw2 Implantattechnologie Gmbh	Knorpelregeneration mit generation von chondronen unter hoher konzentration von magnesium
EP1522322A1 (en) *	2003-10-10	2005-04-13	Witte, Frank, Dr.	Cartilage regeneration
WO2005077405A1 (en) *	2004-02-06	2005-08-25	Cancer Treatment International	Compositions and methods for the treatment of cancer by systemic elevation of lactate and consequent depletion of arginine
US8779175B2 (en)	2004-10-25	2014-07-15	Synthonics, Inc.	Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US20060141054A1 (en)	2004-10-25	2006-06-29	Thomas Piccariello	Metal coordinated compositions
US7799937B2 (en)	2004-10-25	2010-09-21	Synthonics, Inc.	Metal coordinated compositions
FI119101B (fi) *	2006-01-24	2008-07-31	Medgenerics Oy	Magnesiumsuoloja sisältävä hoitoaine kasvainten tai vastaavien hoitoon ja magnesiumsulfaatin käyttö
RU2336076C2 (ru) *	2006-06-22	2008-10-20	Закрытое акционерное общество "Биоамид"	Пероральное лекарственное средство для восполнения дефицита магния в организме
US8945505B2 (en) *	2007-02-02	2015-02-03	Panaphix, Inc.	Use of arsenic compounds for treatment of pain and inflammation
US8815232B2 (en)	2008-08-26	2014-08-26	Kyon Biotech Ag	Compositions and methods for treating cancer
KR102075024B1 (ko) *	2018-01-25	2020-02-07	염창환	마그네슘 화합물을 유효성분으로 포함하는 항암보조제
CN108936149A (zh) *	2018-05-21	2018-12-07	胡宪蕴	一种含纳米硒的多元素复合补充剂及应用
CN109674819B (zh) *	2018-12-21	2023-05-05	博雅干细胞科技有限公司	胎盘间充质干细胞制剂及其治疗硬化病的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5244637A (en) *	1975-10-04	1977-04-07	Fuji Photo Optical Co Ltd	Exposure information display device
IT1124697B (it) *	1979-10-26	1986-05-14	Simes	Derivati di creatinolo o-fosfato ad azione terapeutica,procedimento per la sua preparazione e relativ-e composizioni farmaceutiche
US4975423A (en) *	1984-06-27	1990-12-04	Colgate-Palmolive Company	Inhibition of tumor development
SU1537260A1 (ru) *	1987-08-03	1990-01-23	1-Я Городская Клиническая Больница Г.Новосибирска	Способ предупреждени развити отека набухани головного мозга при черепно-мозговой травме
US5035888A (en) *	1988-11-09	1991-07-30	Tadataka Hara	Therapeutically useful mineral composition
US5977073A (en) *	1991-06-06	1999-11-02	Life Sciences' Technologies, Inc.	Nutrient composition for treatment of immune disorders
US5626883A (en) *	1994-04-15	1997-05-06	Metagenics, Inc.	Ascorbic acid compositions providing enhanced human immune system activity

1994
- 1994-05-25 IT ITRM940328A patent/IT1272994B/it active IP Right Grant
1995
- 1995-05-24 KR KR1019960706651A patent/KR100363031B1/ko not_active Expired - Fee Related
- 1995-05-24 WO PCT/IT1995/000089 patent/WO1995031991A2/en not_active Ceased
- 1995-05-24 PT PT95920208T patent/PT760668E/pt unknown
- 1995-05-24 CN CN95193277A patent/CN1111414C/zh not_active Expired - Fee Related
- 1995-05-24 RU RU96124484/14A patent/RU2163487C2/ru not_active IP Right Cessation
- 1995-05-24 CA CA002190847A patent/CA2190847C/en not_active Expired - Fee Related
- 1995-05-24 ES ES95920208T patent/ES2188663T3/es not_active Expired - Lifetime
- 1995-05-24 DE DE69529213T patent/DE69529213T2/de not_active Expired - Fee Related
- 1995-05-24 AU AU25742/95A patent/AU691617B2/en not_active Ceased
- 1995-05-24 AT AT95920208T patent/ATE229809T1/de not_active IP Right Cessation
- 1995-05-24 US US08/737,743 patent/US6248368B1/en not_active Expired - Fee Related
- 1995-05-24 DK DK95920208T patent/DK0760668T3/da active
- 1995-05-24 EP EP95920208A patent/EP0760668B1/en not_active Expired - Lifetime
- 1995-05-24 JP JP53018295A patent/JP3721196B2/ja not_active Expired - Fee Related
2000
- 2000-12-21 RU RU2000132310/14A patent/RU2000132310A/ru not_active Application Discontinuation
2001
- 2001-05-11 US US09/852,619 patent/US6589564B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2190847A1 (en)	1995-11-30
IT1272994B (it)	1997-07-01
AU691617B2 (en)	1998-05-21
CN1111414C (zh)	2003-06-18
ITRM940328A0 (it)	1994-05-25
RU2000132310A (ru)	2003-01-27
KR100363031B1 (ko)	2003-04-10
CN1149255A (zh)	1997-05-07
AU2574295A (en)	1995-12-18
ATE229809T1 (de)	2003-01-15
JP3721196B2 (ja)	2005-11-30
CA2190847C (en)	2004-03-16
US20010041191A1 (en)	2001-11-15
ES2188663T3 (es)	2003-07-01
US6589564B2 (en)	2003-07-08
EP0760668B1 (en)	2002-12-18
JPH10500678A (ja)	1998-01-20
RU2163487C2 (ru)	2001-02-27
DE69529213D1 (de)	2003-01-30
EP0760668A1 (en)	1997-03-12
US6248368B1 (en)	2001-06-19
ITRM940328A1 (it)	1995-11-25
DE69529213T2 (de)	2003-11-13
WO1995031991A3 (en)	1996-02-15
KR970703155A (ko)	1997-07-03
WO1995031991A2 (en)	1995-11-30
PT760668E (pt)	2003-04-30

Publication	Publication Date	Title
DK0760668T3 (da)	2003-03-31	Anvendelse af magnesiumbaserede produkter til behandling eller forebyggelse af neoplastiske og autoimmune sygdomme
Carson et al.	1996	Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease.
HUT60630A (en)	1992-10-28	Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
KR920000324A (ko)	1992-01-29	필수 지방산 처리법
IT1255390B (it)	1995-10-31	Prodotti farmaceutici per curare malattie tumorali e procedimento per la loro preparazione
BR9908030A (pt)	2000-11-28	Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
BR0109336A (pt)	2003-06-24	Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
GR3021866T3 (en)	1997-03-31	Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
MX9302038A (es)	1993-10-01	Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s.
KR940018089A (ko)	1994-08-16	내부조직의 방사선 손상에 대한 예방 및 처치방법
MY111260A (en)	1999-10-30	Pharmaceutical composition for the treatment of nicotine dependence
EP0957925A4 (en)	2002-07-24	TREATMENT OF OSTEOARTHRITIS BY ADMINISTRATION OF POLY-N-ACETYL-D-GLUCOSAMINE
BR9500436A (pt)	1995-10-17	Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
FR2712811B1 (fr)	1996-01-05	Procédé pour lutter contre l'adiposite et compositions utilisables à cet effet.
KR910005858A (ko)	1991-04-27	지방산 요법
KR920702225A (ko)	1992-09-03	약학 조성물
AU2002334001B2 (en)	2007-07-19	Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia
Eberl et al.	1983	Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study
Omvik et al.	1995	Evaluation and quality-of-life assessment of amlodipine and enalapril in patients with hypertension
JPS57126420A (en)	1982-08-06	Drug for digestive organ
US4650668A (en)	1987-03-17	Composition for relieving toothache pain and other forms of intense pain
WO2001042205A3 (en)	2002-03-21	Treatment of inflammatory bowel disease with vitamin d compounds
CAMPBELL et al.	1969	Pharmacologic agents in the prevention of decompression sickness
Ohizumi	1992	Novel types of cardiotonic drugs
Lee et al.	2018	Vardenafil inhibiting parasympathetic function of tracheal smooth muscle